CTLA-4: From conflict to clinic.
CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7. Uncertainties about its biological function plagued the early years after its discovery until 1995, when it was confirmed to be an inhibitor of T cell responses. CTLA-4 has since scored in the clinic as a target for antitumor therapy and as a soluble inhibitor of autoimmunity.
Bashyam
Hema
H
hbashyam@rockefeller.edu
D015703:Antigens, CD / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use*; D000943:Antigens, Differentiation / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use*; D018122:B7-1 Antigen / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000378:metabolism*; D060908:CTLA-4 Antigen; D049109:Cell Proliferation; D006801:Humans; D007166:Immunosuppressive Agents / Q000276:immunology
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007166:Immunosuppressive Agents